News

A new study by researchers at the University of Manchester suggests that existing FDA-approved drugs may be suitable for repurposing as prophylactics, or for use in combination with vaccine therapy, to ward off COVID-19.

U of M researchers have developed a novel virus-like particle vaccine against COVID-19. Having been successfully tested in animals, the novel vaccine — created as part of a study whose findings were recently published in the scientific journal PLOS Pathogens — offers a new approach in the global battle against COVID-19 and its emerging variants.

Researchers at the University of California San Diego School of Medicine found that breastfeeding mothers who received either the Pfizer-BioNTech or Moderna vaccination reported the same local or systemic symptoms as what has been previously reported in non-breastfeeding women, with no serious side effects in the breastfed infants.

The first experimental vaccine to be tested in the United States for treatment of opioid use disorder is being studied in a phase 1a/1b clinical trial(link is external and opens in a new window) led by researchers at Columbia University Vagelos College of Physicians and Surgeons.

Analysis of tumor biomarkers suggests that immunotherapies may have untapped potential in older cancer patients.

A new study has found that emerging drugs that activate the protein STING alter the activity of metabolic pathways responsible for generating DNA's building blocks.

Nanoengineers at the University of California San Diego have developed COVID-19 vaccine candidates that can take the heat. Their key ingredients? Viruses from plants or bacteria.

Zydus Cadila announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first Plasmid DNA Vaccine for COVID-19.

A peer-reviewed analysis of US national survey data of 75,000 adults shows, from early January to late March, a near “18 percentage point” increase of adults who have either had the COVID-19 vaccine jab or are willing to do have it.

In a new paper, researchers announce what they believe is a major step forward for CRISPR: An efficient, multi-purpose, mini CRISPR system. Whereas the commonly used CRISPR systems – with names like Cas9 and Cas12a denoting various versions of CRISPR-associated (Cas) proteins – are made of about 1000 to 1500 amino acids, their “CasMINI” has 529.